PICOLAX

This brand name is authorized in Ireland, Malta, United Kingdom, South Africa

Active ingredients

The drug PICOLAX contains a combination of these active pharmaceutical ingredients (APIs):

1 Citric acid
UNII XF417D3PSL - ANHYDROUS CITRIC ACID

Potassium citrate is indicated for the management of renal tubular acidosis with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, uric acid lithiasis with or without calcium stones. When potassium citrate is given orally, the metabolism of absorbed citrate produces an alkaline load. The induced alkaline load in turn increases urinary pH and raises urinary citrate by augmenting citrate clearance without measurably altering ultrafilterable serum citrate. Thus, potassium citrate therapy appears to increase urinary citrate principally by modifying the renal handling of citrate, rather than by increasing the filtered load of citrate.

Read about Citric acid
2 Magnesium oxide
UNII 3A3U0GI71G - MAGNESIUM OXIDE

Magnesium oxide (MgO), or magnesia, is an empirical formula of MgO and consists of a lattice of Mg2+ ions and O2− ions held together by ionic bonding.

Read about Magnesium oxide
3 Sodium picosulfate
UNII LR57574HN8 - SODIUM PICOSULFATE

Sodium picosulfate is a locally acting laxative from the triarylmethane group, which after bacterial cleavage in the colon, has a dual-action with stimulation of the mucosa of both the large intestine and of the rectum.

Read about Sodium picosulfate

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
PICOLAX Powder for oral solution Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
A06AB58 Sodium picosulfate, combinations A Alimentary tract and metabolism → A06 Laxatives → A06A Laxatives → A06AB Contact laxatives
Discover more medicines within A06AB58

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 332149, 39166
Country: MT Medicines Authority Identifier(s): AA1314/00401
Country: ZA Health Products Regulatory Authority Identifier(s): A39/11.5/0058

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.